Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Tuesday 04 January 2022 7:42 am

Boost white blood cells in immune system as they are able to fight off Omicron variant, Covid scientists find

By: Michiel Willems

Add as a preferred source on Google
PCR-TEST-KIT-FIRM
A student taking a PCR test

The immune system’s white blood cells are able to mount an immune response against the Omicron variant of Covid-19, according to a new study.

Due to Omicron having a higher number of mutations than other Covid variants, it can sometimes slip past the antibodies created by vaccination or infection.

However, if the virus still does enter the body, the white blood cells, known as T-cells, will attack.

The new research, from the University of Melbourne and Hong Kong University of Science and Technology (HKUST), involved investigators analysing over 1,500 fragments of SARS-CoV-2’s viral proteins – called epitopes – that have been found to be recognised by T-cells in recovered Covid-19 patients or after vaccination.

The team’s findings, published in the peer-reviewed journal Viruses, suggest Omicron is unlikely to be able to evade T-cells, adding to a growing body of evidence from research groups around the world who are also investigating T-cell responses to Covid-19.

University of Melbourne professor and co-leader of the research, Matthew McKay, said: “Despite being a preliminary study, we believe this is positive news.

“Even if Omicron, or some other variant for that matter, can potentially escape antibodies, a robust T-cell response can still be expected to offer protection and help to prevent significant illness.

“Based on our data, we anticipate that T-cell responses elicited by vaccines and boosters, for example, will continue to help protect against Omicron, as observed for other variants. We believe this presents some positive news in the global fight against Omicron.”

According to the researchers, the most concerning aspect of Omicron is the abundance of mutations in its spike protein, which is the primary target of Covid-19 vaccines. The spike enables the virus to attach and enter cells in humans.

Current vaccines induce neutralising antibodies aimed at blocking this process, however these antibodies have been reported to be less effective against Omicron compared with previous variants.

In analysing virus epitopes from the spike protein that are targeted by T-cells in vaccinated or previously infected individuals, the study found that only 20% showed mutations associated with Omicron.

Even then, these mutations do not necessarily mean the virus will be able to evade the body’s T-cells, researchers said.

Read more

Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Media

Related Topics

  • Pharmaceuticals
  • Pharmaceuticals

Trending Articles

  • Billionaire Easyjet founder in line for £800m payday from takeover

  • Burnham told to launch £100bn tax reform package

  • Construction sector cuts jobs again as house building slumps

  • Pension pressure to help swell UK debt to three times size of economy

  • Harry Styles at Wembley Stadium review: running through the grief

More from City PM

  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • morph Launches the World’s First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications

    Business Wire
  • IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

    Business Wire
  • IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Dr Mom Hand Unveils Phyto-Resonance®

    Business Wire
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy